Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo-Nordisk/Smith Kline & French

Executive Summary

Two firms will develop and commercialize neuronal calcium channel blockers for the treatment of stroke and central nervous system disorders using compounds discovered by Novo-Nordisk's A/S Ferrosan subsidiary. Under the agreement, Novo-Nordisk will market the products in Europe, while SK&F retains exclusive rights outside of Europe. The agreement is the first between Novo-Nordisk and SK&F.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel